Effects of treatment with a 5‐HT4receptor antagonist in heart failure

Authors:

Abstract
Background and purpose: Positive inotropic responses (PIR) to 5‐hydroxytryptamine (5‐HT) are induced in the left ventricle (LV) in rats with congestive heart failure (CHF); this is associated with upregulation of the Gs‐coupled 5‐HT4receptor. We investigated whether chronic 5‐HT4receptor blockade improved cardiac function in CHF rats.Experimental approach: Rats were given either the 5‐HT4antagonist SB207266 (0.5 mg kg−124h−1; MIint) or placebo (MIpl) through mini‐osmotic pumps for 6 weeks subsequent to induction of post‐infarction CHF.In vivocardiac function andex vivoresponses to isoprenaline or 5‐HT were evaluated using echocardiography and isolated LV papillary muscles, respectively. mRNA levels were investigated using real‐time quantitative RT‐PCR.Key results: LV diastolic function improved, with 4.6% lower LV diastolic diameter and 24.2% lower mitral flow deceleration in MIintcompared to MIpl. SB207266 reduced LV systolic diameter by 6.1%, heart weight by 10.2% and lung weight by 13.1%. The changes in posterior wall thickening and shortening velocity, cardiac output, LV systolic pressure and (dP/dt)max, parameters of LV systolic function, did not reach statistical significance. The PIR to isoprenaline (10 μM) increased by 36% and the response to 5‐HT (10 μM) decreased by 57% in MIintcompared to MIpl. mRNA levels for ANP, 5‐HT4(b)and 5‐HT2Areceptors, MHCβ, and the MHCβ/MHCα‐ratio were not significantly changed in MIintcompared to MIpl.Conclusions and implications: Treatment with SB207266 to some extent improvedin vivocardiac function andex vivomyocardial function, suggesting a possible beneficial effect of treatment with a 5‐HT4receptor antagonist in CHF.British Journal of Pharmacology(2007)150, 143–152. doi:10.1038/sj.bjp.0706966

This publication has 53 references indexed in Scilit: